Literature DB >> 6130897

Improvement in ventilation-perfusion matching by almitrine in COPD.

C Mélot, R Naeije, T Rothschild, P Mertens, P Mols, R Hallemans.   

Abstract

Almitrine, a peripheral chemoreceptor stimulating drug, was given 100 mg orally to six patients with advanced chronic obstructive pulmonary disease (COPD), and its effects on hemodynamics, blood gases, lung mechanics, and the distribution of ventilation/perfusion ratios (VA/Q), determined by the inert gas elimination technique, were investigated. Arterial Po2 increased from 52 +/- 4 to 59 +/- 3 mm Hg, mean +/- SEM, p less than 0.01, arterial Pco2 decreased from 46 +/- 3 to 43 +/- 3 mm Hg, p less than 0.05, and venous admixture from 30 +/- 6 to 19 +/- 3 percent, p less than 0.02. No change occurred in ventilation, variables of lung mechanics, systemic and pulmonary hemodynamics, except an increase in pulmonary vascular resistance (from 364 +/- 103 to 438 +/- 99 dyne.s.cm-5, p less than 0.05). A reduction in VA/Q inequality could be demonstrated with a redistribution of blood flow into the lungs by a diversion of 15 percent of total blood flow from units with low VA/Q (between 0.08 and 0.4) to units with normal VA/Q (between 0.5 and 1.8). These changes might be explained by an enhancement of hypoxic pulmonary vasoconstriction. Pharmacologic peripheral chemoreceptor stimulation, at an infra-ventilatory analeptic dosage, might be of therapeutic interest to patients with respiratory insufficiency due to VA/Q inequality.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6130897     DOI: 10.1378/chest.83.3.528

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  19 in total

1.  Tidal lung recruitment and exhaled nitric oxide during coronary artery bypass grafting in patients with and without chronic obstructive pulmonary disease.

Authors:  Alysson R Carvalho; Fumito Ichinose; Ivany A Schettino; Dean Hess; Javier Rojas; Antonio Giannella-Neto; Arvind Agnihotri; Jennifer Walker; Thomas E MacGillivray; Marcos F Vidal Melo
Journal:  Lung       Date:  2011-09-28       Impact factor: 2.584

Review 2.  The pulmonary circulation in acute lung injury: a review of some recent advances.

Authors:  M Leeman
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

Review 3.  The role of nitric oxide in sepsis and ARDS: synopsis of a roundtable conference held in Brussels on 18-20 March 1995.

Authors:  M P Fink; D Payen
Journal:  Intensive Care Med       Date:  1996-02       Impact factor: 17.440

Review 4.  The use, and misuse, of exogenous endothelial-derived vasodilators in acute respiratory failure.

Authors:  A T Dinh-Xuan; F Brunet; J F Dhainaut
Journal:  Intensive Care Med       Date:  1997-11       Impact factor: 17.440

Review 5.  NO: COPD and beyond.

Authors:  A T Jones; T W Evans
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

6.  Almitrine bismesylate and oxygen therapy in hypoxic cor pulmonale.

Authors:  T W Evans; J Tweney; J C Waterhouse; J Nichol; A J Suggett; P Howard
Journal:  Thorax       Date:  1990-01       Impact factor: 9.139

7.  Chronic respiratory failure in COPD: is there a place for a respiratory stimulant?

Authors:  P A Bardsley
Journal:  Thorax       Date:  1993-08       Impact factor: 9.139

Review 8.  Contribution of multiple inert gas elimination technique to pulmonary medicine. 2. Chronic pulmonary diseases: chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.

Authors:  A G Agustí; J A Barberà
Journal:  Thorax       Date:  1994-09       Impact factor: 9.139

Review 9.  Management of chronic obstructive pulmonary disease.

Authors:  S Kesten; A S Rebuck
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

Review 10.  Hypoxic Pulmonary Vasoconstriction: From Molecular Mechanisms to Medicine.

Authors:  Kimberly J Dunham-Snary; Danchen Wu; Edward A Sykes; Amar Thakrar; Leah R G Parlow; Jeffrey D Mewburn; Joel L Parlow; Stephen L Archer
Journal:  Chest       Date:  2016-09-16       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.